<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087256</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP P-3</org_study_id>
    <secondary_id>NSABP-P-3</secondary_id>
    <nct_id>NCT00087256</nct_id>
  </id_info>
  <brief_title>Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer</brief_title>
  <official_title>Celecoxib Polyp Prevention Trial in Participants With Resected Stage I Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development of cancer. It is not yet known whether celecoxib is effective in preventing&#xD;
      polyps in patients with colon cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to study the effectiveness of celecoxib in preventing the&#xD;
      development of polyps in patients who have undergone surgery for stage I colon cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare celecoxib vs placebo, in terms of decreasing the incidence of adenomatous polyps&#xD;
           of the colon and rectum, in patients with resected stage I adenocarcinoma of the colon.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare disease-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the effect of these regimens on self-reported symptoms and health-related&#xD;
           quality of life of these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the benefits of celecoxib in patients with primary tumors or polyps that express&#xD;
           cyclo-oxygenase-2 (COX-2) with those that do not express COX-2.&#xD;
&#xD;
        -  Compare the expression of signaling targets such as serine/threonine AKT, extracellular&#xD;
           signal-regulated kinase 2 (ERK2), and endoplasmic reticulum Ca+2- ATPases in the index&#xD;
           tumor and polyps.&#xD;
&#xD;
        -  Determine the toxicity and safety of celecoxib in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to gender, tumor stage (T1 vs T2), age (≤ 49 vs 50 to 59 vs ≥ 60&#xD;
      years), and current aspirin use (yes vs no). Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral celecoxib twice daily for 3 years.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo twice daily for 3 years. In both arms, treatment&#xD;
           continues in the absence of unacceptable toxicity or the diagnosis of invasive colon&#xD;
           cancer, carcinoma in situ of the colon or rectum, or a non-colon primary cancer.&#xD;
&#xD;
      Quality of life is assessed at baseline and then at 6, 12, 24, 36, and 42 months.&#xD;
&#xD;
      Patients are followed at 6 months and at 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1,200 patients (600 per treatment arm) will be accrued for this&#xD;
      study within 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    For scientific, logistic, and administrative reasons.&#xD;
  </why_stopped>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether celecoxib 400 mg bid for 3 years will decrease the incidence of adenomatous polyps of the colon and rectum in participants with Stage I adenocarcinoma of the colon.</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To access whether celecoxib will increase disease-free survival.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To access whether celecoxib therapy affects self-reported symptoms and health-related quality of life.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the quality of life in early stage colon cancer patients.</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate if the benefits from celecoxib are more pronounced in a cohort of participants whose primary colon tumors and polyps express COX-2.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine the expression of signaling targets such as serine/threonine kinase (AKT) extracellular signal-regulated kinase (ERK2), and endoplasmic reticulum Ca2+-ATPases in the index tumor and polyps.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To monitor the toxicity and safety of celecoxib in this population.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one placebo capsule taken orally twice a day for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one 400 mg capsule taken orally twice a day for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <arm_group_label>Arm 1: placebo</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Arm 2: celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon&#xD;
&#xD;
               -  Stage I disease&#xD;
&#xD;
               -  Distal border of tumor ≥ 12 cm from the anal verge&#xD;
&#xD;
          -  Tumor completely resected within the past 90 days&#xD;
&#xD;
          -  Must have undergone a preoperative or postoperative colonoscopy to the cecum (or small&#xD;
             bowel anastomosis) within the past 90 days&#xD;
&#xD;
               -  All observed polyps must have been removed&#xD;
&#xD;
          -  Patients with a history suggestive of hereditary non-polyposis colorectal cancer&#xD;
             (HNPCC) must have a normal microsatellite instability status by immunohistochemistry&#xD;
             or polymerase chain reaction&#xD;
&#xD;
               -  Patients with family history of colon cancer who have not been diagnosed with&#xD;
                  HNPCC are eligible&#xD;
&#xD;
          -  No prior familial adenomatous polyposis&#xD;
&#xD;
          -  No prior invasive cancer or carcinoma in situ of the colon or rectum&#xD;
&#xD;
          -  No clinical or radiologic evidence of metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 10 years&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Complete blood count normal&#xD;
&#xD;
          -  Platelet count normal&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Alkaline phosphatase normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No active ischemic heart disease&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No symptomatic arrhythmia&#xD;
&#xD;
          -  No symptomatic peripheral vascular disease or carotid disease that would preclude&#xD;
             study participation&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No aspirin-sensitive asthma&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No history of inflammatory bowel disease&#xD;
&#xD;
          -  No history of upper gastrointestinal bleeding&#xD;
&#xD;
          -  No history of duodenal or gastric ulcer&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No known hypersensitivity to any COX-2 inhibitor, NSAIDs, aspirin, or sulfonamides&#xD;
&#xD;
          -  No non-colorectal malignancy within the past 5 years except carcinoma in situ of the&#xD;
             cervix, melanoma in situ, or basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No other disease that would preclude study participation&#xD;
&#xD;
          -  No psychiatric disorders, including history of clinical depression or addictive&#xD;
             disorders, that would preclude giving informed consent or long-term compliance&#xD;
&#xD;
          -  No rheumatologic or skeletal disorders requiring chronic NSAIDs or steroid therapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents for colon cancer&#xD;
&#xD;
          -  No concurrent chronic use of other cyclo-oxygenase-2 (COX-2) inhibitors, non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs), or salicylates (e.g., aspirin)&#xD;
&#xD;
               -  Chronic use is defined as use for more than an average of 3 days per month&#xD;
&#xD;
                    -  Concurrent NSAIDs allowed for up to 10 consecutive days for temporary relief&#xD;
                       due to inflammatory syndromes, injury, or postoperative pain&#xD;
&#xD;
               -  Cardioprotective doses of aspirin (≤ 81 mg/day or 325 mg every other day) allowed&#xD;
&#xD;
          -  No concurrent fluconazole or lithium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I colon cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

